? FLOW CYTOMETRY SHARED RESOURCE Shared Resource Leader: Jordi Ochando, PhD The Tisch Cancer Institute (TCI) Flow Cytometry Shared Resource Facility (FCSRF) provides TCI members access to state-of-the-art technology and expertise for the successful development of scientific research projects. Flow cytometry is a powerful technology that enables researchers to study simultaneous multiparametric characteristics of thousands of cells per second to decipher complex cellular and molecular processes in health and disease. The FCSRF offers services for routine applications such as single cell isolation to rapidly isolate live cells conduct more innovative and complex biological studies such as RNAseq, metabolomics, and lipidomics assays. The FCSRF is comprised of the institutional Flow Cytometry Shared Resource Facility and two TCI satellite sites. The FCSRF is equipped with 4 analyzers, 2 mouse cell sorters, 3 cell sorters contained in biosafety level 2+ areas dedicated to isolate non-fixed human samples and mouse cells infected with class II pathogens, and 1 mass cytometer (CyTOF). In addition, two satellite sites are equipped with 4 analyzers. Staffed with 7 flow and mass cytometry specialists committed at 100% to this facility, the SRF provides operational, training, and consultation services covering all aspects of flow cytometry including cell cycle analysis, isolation single cells from cancer patients, and identification of over 30 different cell surface/intracellular antigens on the same cell using mass cytometry. With this in mind, our mission is to provide the necessary instrumentation and knowledge regarding flow/mass cytometry and cell sorting so that Tisch Cancer Institute investigators improve human cancer diagnosis and treatment through basic sciences, translational, and clinical research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA196521-01
Application #
8932184
Study Section
Subcommittee G - Education (NCI)
Project Start
2015-08-01
Project End
2020-07-31
Budget Start
2015-08-01
Budget End
2016-07-31
Support Year
1
Fiscal Year
2015
Total Cost
$92,548
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Serasinghe, Madhavika N; Gelles, Jesse D; Li, Kent et al. (2018) Dual suppression of inner and outer mitochondrial membrane functions augments apoptotic responses to oncogenic MAPK inhibition. Cell Death Dis 9:29
Abbate, Franco; Badal, Brateil; Mendelson, Karen et al. (2018) FBXW7 regulates a mitochondrial transcription program by modulating MITF. Pigment Cell Melanoma Res :
Linde, Nina; Casanova-Acebes, Maria; Sosa, Maria Soledad et al. (2018) Macrophages orchestrate breast cancer early dissemination and metastasis. Nat Commun 9:21
Sonoshita, Masahiro; Scopton, Alex P; Ung, Peter M U et al. (2018) A whole-animal platform to advance a clinical kinase inhibitor into new disease space. Nat Chem Biol 14:291-298
Hirschfield, Hadassa; Bian, C Billie; Higashi, Takaaki et al. (2018) In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment. Exp Mol Med 50:e419
Rattay, T; Symonds, R P; Shokuhi, S et al. (2018) The Patient Perspective on Radiogenomics Testing for Breast Radiation Toxicity. Clin Oncol (R Coll Radiol) 30:151-157
Fujiwara, Naoto; Friedman, Scott L; Goossens, Nicolas et al. (2018) Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 68:526-549
Braza, Mounia S; Conde, Patricia; Garcia, Mercedes et al. (2018) Neutrophil derived CSF1 induces macrophage polarization and promotes transplantation tolerance. Am J Transplant 18:1247-1255
Van Renne, Nicolaas; Roca Suarez, Armando Andres; Duong, Francois H T et al. (2018) miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Gut 67:953-962
Deshmukh, Manjeet; Nakagawa, Shigeki; Higashi, Takaaki et al. (2018) Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. Nanomedicine 14:317-325

Showing the most recent 10 out of 143 publications